4 assets in Synucleinopathy

Therapeutic assets addressing Synucleinopathy, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Rasagiline Synucleinopathy	Second Affiliated Hospital, School of Medicine, Zhejiang University	P2/3	B (57)
Donanemab Synucleinopathy	Eli Lilly and Company	P2	CCC (53)
Tenapanor Synucleinopathy	Cedar Valley Digestive Health Center	P2	CCC (52)